Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy

被引:14
|
作者
Poole, Chris D. [1 ]
Bannister, Christian A. [1 ]
Andreasen, Jakob Norgaard [2 ]
Andersen, Jens Strodl [2 ]
Currie, Craig J. [1 ]
机构
[1] Cardiff Univ, Cochrane Inst Primary Care & Publ Hlth, Cardiff CF10 3AX, S Glam, Wales
[2] ALK, Horsholm, Denmark
基金
英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
QUALITY-OF-LIFE; RHINITIS; CONJUNCTIVITIS; PREVALENCE; SEVERITY; TABLETS; BURDEN; MODELS; IMPACT; COST;
D O I
10.1186/1477-7525-12-99
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Grass allergen immunotherapy (AIT) reduces symptom severity in seasonal allergic rhinoconjunctivitis (ARC) but its impact on general health-related utility has not been characterised for the purposes of economic evaluation. The aim of this study was to model the preferred measure of utility, EQ-5D index, from symptom severity and estimate incremental quality adjusted life years (QALYs) associated with SQ-standardised grass immunotherapy tablet (GRAZAX (R), 75,000 SQ-T/2,800 BAU, ALK, Denmark). Methods: Data were analysed from five consecutive pollen seasons in a randomised placebo controlled trial of GRAZAX (R). Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and medication scores (DSS & DMS respectively). In turn, daily EQ-5D index was estimated from ARC symptoms and medication use. Results: DSS and DMS were the principal predictors of 'perfect' health (EQ-5D = 1.000; binomial) and 'imperfect' health (EQ-5D < 1.000; Gaussian). Each unit increase in DSS and DMS reduced the odds of 'perfect' health (EQ-5D = 1.000) by 27% and 16% respectively, and reduced 'imperfect' health by 0.17 and 0.13, respectively. Gender remained the only other significant main fixed effect (Male odds ratio [OR] = 1.82). Incremental estimated EQ-5D index utility for GRAZAX (R) was observed from day -30 to day +70 of the pooled pollen season; mean daily utility for GRAZAX (R) = 0.938 units (95% CI 0.932-0.943) vs. 0.914 (0.907-0.921) for placebo, an incremental difference of 0.0238 (p < 0.001). This translates into an incremental 0.0324 Quality Adjusted Life Years over the five year study period. Conclusions: ARC symptoms and medication use are the main predictors of EQ-5D index. The incremental QALYs observed for GRAZAX (R) may not fully describe the health benefits of this treatment, suggesting that economic modelling may be conservative.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Health-related quality of life in Parkinson's disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores
    Bhanupriya, Raghu
    Haridoss, Madhumitha
    Lakshmi, Goda Suchitra
    Bagepally, Bhavani Shankara
    QUALITY OF LIFE RESEARCH, 2024, 33 (07) : 1781 - 1793
  • [22] Health-related quality of life among patients with gallstone disease: a systematic review and meta-analysis of EQ-5D utility scores
    Deborah, Y. ArpithaAnbu
    Haridoss, Madhumitha
    Natarajan, Meenakumari
    Joshua, Vasna
    Bagepally, Bhavani Shankara
    QUALITY OF LIFE RESEARCH, 2022, 31 (08) : 2259 - 2266
  • [23] A cross sectional survey on health-related quality of life among parents of children with allergic symptoms using the EQ-5D-5L
    Hwang, Tae-Yoon
    Kim, Sang-Kyu
    Kim, Seon-Ha
    Kim, Miok
    JOURNAL OF ASTHMA, 2019, 56 (11) : 1239 - 1245
  • [24] Investigating Differences in Health-Related Quality of Life of Greeks and Albanian Immigrants with the Generic EQ-5D Questionnaire
    Lahana, Eleni
    Niakas, Dimitris
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [25] A scoping review of the use of minimally important difference of EQ-5D utility index and EQ-VAS scores in health technology assessment
    Shaw, Caroline
    Longworth, Louise
    Bennett, Bryan
    McEntee-Richardson, Louise
    Shaw, James W.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2024, 22 (01)
  • [26] Variations in health-related quality of life (EQ-5D) associated with cardiovascular health: a cross-sectional study of adults with diabetes in the Korean general population
    Jung, Hyejin
    BMJ OPEN, 2024, 14 (05): : 1 - 8
  • [27] Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-5D)
    Hurst, NP
    Kind, P
    Ruta, D
    Hunter, M
    Stubbings, A
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (05): : 551 - 559
  • [28] Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients
    Prieto, L
    Sacristan, JA
    Hormaechea, JA
    Casado, A
    Badia, X
    Gómez, JC
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (06) : 827 - 835
  • [29] Factors affecting health-related quality of life among hypertensive patients using the EQ-5D tool
    Alefishat, Eman
    Jarab, Anan S.
    Abu Farha, Rana
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (09)
  • [30] Health-Related Quality of Life Measured by EQ-5D in Relation to Hospital Stay and Readmission in Elderly Patients Hospitalized for Acute Illness
    Lin, Cheng-Fu
    Huang, Yu-Hui
    Ju, Li-Ying
    Weng, Shuo-Chun
    Lee, Yu-Shan
    Chou, Yin-Yi
    Lin, Chu-Sheng
    Lin, Shih-Yi
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (15) : 1 - 10